Affiliation:
1. Department of Chemistry and Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, Georgia 30303, United States
2. Proterris, Inc., Boston, MA, United States
Abstract
The quest to find novel strategies to tackle respiratory illnesses has led to the exploration
of the potential therapeutic effects of carbon monoxide (CO) as an endogenous signaling
molecule and a cytoprotective agent. Further, several studies have demonstrated the pharmacological
efficacy of CO in animal models of respiratory disorders, such as acute lung injury and pulmonary
hypertension. Because of the gaseous nature of CO and its affinity for multiple targets, its controlled
delivery has been a challenge. Past studies have employed different delivery modalities, including
CO gas, HO-1 inducers, and CO donors, sometimes leading to substantive variations in the
resulting pharmacological effects for various reasons. Herein, this review summarizes and analyzes
the differences among the profiles of various CO-delivery modalities in terms of their efficacy, dosing
regimen, and pharmacokinetics in airways models. We believe that analysis of these issues will
help in understanding the fundamental roles of CO in airways, and eventually, contribute to its development
as a medicine for respiratory diseases.
Funder
National Institutes of Health
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,General Medicine
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献